press

MEDIPOST is a special biotechnology company in studying and manufacturing stem cell drugs and umbilical cord blood.
113 2 팔로워
소이현-인교진 부부도 자녀 제대혈 보관 동참

소이현-인교진 부부도 자녀 제대혈 보관 동참

Nikkei Japan Reports the Status of MEDIPOST’s Stem Cell Research

Nikkei Japan Reports the Status of MEDIPOST’s Stem Cell Research

Core dementia treatment technology patented at 6 European countries, concurrently

Core dementia treatment technology patented at 6 European countries, concurrently

Quantity of Cord Blood under Custody Exceeds 200,000 Units for the First Time in Korea

Quantity of Cord Blood under Custody Exceeds 200,000 Units for the First Time in Korea

Accumulated Dosage of CARTISTEM Exceeds 2,000 Cases

Accumulated Dosage of CARTISTEM Exceeds 2,000 Cases

Administration of lung disease medicine Pneumostem started in U.S. clinical trial

Administration of lung disease medicine Pneumostem started in U.S. clinical trial

Administration of lung disease medicine ‘Pneumostem’ in clinical trial completed

Administration of lung disease medicine ‘Pneumostem’ in clinical trial completed

The only Korean company invited to North American Rare Medicine conference

The only Korean company invited to North American Rare Medicine conference

Participation in Biotec Japan and local publicity activities on CARTISTEM

Participation in Biotec Japan and local publicity activities on CARTISTEM

Administration of lung disease medicine Pneumostem started in U.S. clinical trial

Administration of lung disease medicine Pneumostem started in U.S. clinical trial

Pinterest
검색